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Abstract
Background: Depressive symptoms are quite prevalent in Primary Care (PC) settings. The treatment as usual (TAU)
in PC is pharmacotherapy, despite the high relapse rates it produces. Many patients would prefer psychotherapy,
but specialized services are overloaded. Studies that apply Mindfulness-Based Interventions (MBIs) for the treatment
of depression have obtained significant improvements. Brief low-intensity approaches delivered from PC could be a
promising approach. This study aims to compare a low-intensity mindfulness intervention for the treatment of
depression in PC using different intervention formats – a face-to-face MBI delivered in a group and the same MBI
individually applied on the Internet – to a control group that will receive PC medical treatment as usual.
Methods: A randomized controlled clinical trial will be conducted in PC, with about 120 depressed patients
allocated (1:1:1) to three groups: “face-to-face MBI + TAU”, “Internet-delivered MBI + TAU”, and “TAU alone”. The MBI
programs will be composed of four modules. The primary outcome will be depressive symptoms, measured
through the Beck Depression Inventory, assessed at pre- and post-treatment and 6- and 12-month follow-ups.
Other outcomes will be mindfulness, happiness, affectivity, quality of life, and the use of healthcare services.
Intention-to-treat analysis using linear mixed models adjusted for baseline scores and routine sociodemographic
analysis that could show baseline differences will be conducted. Per-protocol secondary outcome analyses will also
be performed.
Discussion: This is the first Spanish RCT to apply a low-intensity face-to-face MBI (plus TAU) to treat depression in
PC settings compared to TAU (alone). Moreover, this study will also make it possible to evaluate the same MBI
program (plus TAU), but Internet-delivered, considering their cost-effectiveness. Positive results from this RCT might
have an important impact on mental health settings, helping to decrease the overload of the system and offering
treatment alternatives beyond antidepressant medication through high-quality, flexible PC interventions.
Trial registration: Clinical Trials.gov NCT03034343. Trial Registration date 24 January 2017, retrospectively registered.
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Randomized controlled trial
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: squero@uji.es
1Universitat Jaume I, Av. Vicente Sos Baynat s/n, 12006 Castellón, Spain
2CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid,
Spain
Full list of author information is available at the end of the article
Lopez-Montoyo et al. BMC Psychiatry          (2019) 19:301 
https://doi.org/10.1186/s12888-019-2298-x
Background
Major Depression is a common mental disorder that
produces great functional and social impairment all over
the world. It is characterized by sustained states of nega-
tive affectivity and diminished positive affectivity. Ac-
cording to the World Health Organization (WHO), in
2020, this disorder will be the second most important
cause of disability [1]. It has been estimated that around
14.0% of the European population have suffered from a
lifetime history of major depressive disorder [2]. Specif-
ically in Primary Care (PC) settings, a meta-analysis
reviewing its prevalence in more than ten countries
showed that the overall prevalence of depression was
19.5% [3]. In the Spanish population, prevalence rates of
29.0% have been observed for major depressive disorder
and 14.6% for dysthymia in PC services [4].
Although previous studies have reported that a com-
bination of psychotherapy and pharmacotherapy is the
best treatment option [5], the usual intervention in PC
settings is pharmacotherapy alone, even though it pro-
duces high relapse rates [6, 7] that increase with each
depressive episode [8]. Some patients prefer psychother-
apy to pharmacological treatment [9], but it should be
noted that Spanish specialized services are overloaded.
Moreover, it is difficult to introduce psychotherapy in
PC due to problems such as the professionals’ training,
high costs or work overload, professionals’ attitudes and
organization, geographical and logistic difficulties, and,
especially, lack of time [10]. All these problems reveal
the need to offer new forms of treatment for depression
in PC, and low-intensity interventions seem to be a
promising solution.
On the one hand, interventions that are considered
low intensity are either not guided (e.g. self-help) by
highly qualified facilitators, or they are guided by highly
qualified facilitators for only a short time [11]. On the
other hand, brief interventions have been operationalized
as consisting of more than two and less than ten ap-
pointments [12]. Although brief psychotherapies for de-
pression are an alternative that has already been shown
to be effective [13], a systematic review of low-intensity
psychological interventions for depression revealed the
need for more studies [9]. Mindfulness-based interven-
tions (MBIs) have demonstrated their effectiveness in
the treatment and prevention of relapse or recurrence of
depression. Specifically, Mindfulness-Based Cognitive
Therapy (MBCT), an intervention that combines mind-
fulness training and elements of cognitive therapy [14],
has shown significant effects in patients with diagnostic
levels of depression. In fact, NICE guidelines recom-
mend it as the treatment of choice for depression recur-
rence [15]. Although there is no agreement on this
topic, many authors believe that MBIs included under
the umbrella of “third wave” cognitive behavioral therapy
can be considered low intensity interventions. Some
studies have demonstrated beneficial effects of brief
mindfulness-based interventions in non-clinical popula-
tions [16–19].
In addition, internet-based treatments have been
found to be promising for numerous mental health
problems, including depressive symptoms [20], and for
increasing the dissemination of evidence-based treat-
ments [21]. The main advantages of these types of pro-
grams are that they reduce the contact time between the
patient and the clinician, and they reach patients who
would not otherwise receive treatment or are geograph-
ically distant. In addition, receiving treatment at home
ensures confidentiality, minimizes stigma, and reduces
the difficulty some people have when receiving psycho-
logical treatment [21]. Several systematic reviews have
shown that Internet-based treatments based on Cogni-
tive Behavioral Therapy (CBT) are effective, acceptable,
and practical for the treatment of health problems such
as anxiety and depressive disorders [22–25]. Further-
more, even self-guided online psychological treatments
for depressive symptoms have been found to produce
higher effect sizes compared to control groups [22], and
in general, online treatments seem to be as efficacious as
face-to-face treatment as usual for depression [5, 26, 27].
In the case of mindfulness, some studies have applied
MBIs over the Internet with good results [28–30], but a
literature review and meta-analysis have shown that, al-
though online MBIs have significant effects on improv-
ing mental health, these effects could be small to
moderate. Moreover, both studies concluded that more
research is needed using more rigorous methods and
examining long-term effects and moderators of online
MBIs [27, 31].
Therefore, due to the need for further research about
the possible benefits of low intensity interventions in PC
settings and brief MBI applications, this study aims to
compare a low-intensity mindfulness intervention for
the treatment of depression in PC using different inter-
vention formats – a face-to-face MBI in a group format
(6-8 people/group) and the same MBI but individually
applied on the Internet – to a control group receiving
PC medical treatment as usual (TAU). The cost-
effectiveness of the intervention formats, compared to
TAU, is also evaluated.
The main hypothesis is that the MBI programs (face-
to-face and online) will be more effective than TAU.
Furthermore, improvements are also expected in sec-
ondary outcome measures (depression, positive and
negative affect, and happiness) and other measures
(health-related quality of life, mindfulness skills) in both
intervention groups, compared to the TAU group. Add-
itionally, the differences between face-to-face and online
formats will be explored because, to our knowledge,
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there are no studies to date that compare MBIs applied
online vs. face-to-face in this population. Finally, regard-
ing cost-effectiveness, we expect that both MBI interven-
tions will be more cost-effective than TAU. Additionally,
cost-effectiveness differences between face-to-face and
online formats will be explored.
Methods
Study design
Participants will be randomly allocated to a three-armed
randomized controlled clinical trial with three condi-
tions: a) “face-to-face MBI + TAU”, b) “Internet-deliv-
ered MBI + TAU”, and c) “TAU alone”. They will be
assessed at pre- and post-treatment and 6- and 12-
month follow-ups. The study flowchart is shown in
Fig. 1. The study is currently in progress in the data re-
cruitment stage.
This study will follow the CONSORT statement (Con-
solidated Standards of Reporting Trials, http://www.con-
sort-statement.org) [32] and the SPIRIT guidelines
(Standard Protocol Items: Recommendations for Inter-
vention Trials) [33]. The study’s trial registration num-
ber is ClinicalTrials.gov NCT03034343.
Ethics
This study will be conducted according to the inter-
national standards of the Declaration of Helsinki and
subsequent amendments. This trial will be performed in
compliance with the study protocol and with good clin-
ical practice guidelines with the main aim of protecting
and preserving human rights [34]. Data security will be
Fig. 1 Flowchart of the study
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guaranteed, the participants included in the study will be
protected by the Organic Law on Protection of Personal
Data (15/1999 of December 13, LOPD) and all relevant
EU legislation in this regard, and international privacy
agreements will be observed and respected. The Internet
platform will be accessed through a unique username +
password combination. An advanced encryption stand-
ard will be used to protect the data (AES-256). The
study has been approved by the Ethics Committee of
Universitat Jaume I (Castellón, Spain) and the Ethics
Committee of Aragón (Zaragoza, Spain). An informed
consent form will be signed by participants before
randomization. Participants allocated to the TAU arm
will also be offered the possibility of receiving the psy-
chotherapy program through the format they prefer with
all the contents and materials at the end of the study.
Study population, recruitment, and eligibility criteria
This randomized controlled clinical trial will be con-
ducted from the Health Center of Arrabal in Zaragoza
(Spain). Participants will be adult PC outpatients
attended to by their corresponding General Practitioners
(GP), and they will be recruited by GPs working in the
different Health Centers in Zaragoza (Spain). The re-
searchers who manage the study will go to the different
Health Centers to explain the study and eligibility cri-
teria to the GPs, and they will give them an information
sheet containing the study characteristics.
When a GP identifies a potential patient, s/he will ex-
plain the study to him/her and inform him/her that s/he
can refuse to participate or withdraw from the study at
any time, without any negative effects on their profes-
sional relationship or on future treatments that might be
offered to the participant in PC. If the patient is inter-
ested, s/he will have to come to the Arrabal Health Cen-
ter to clarify any doubts about the study and sign an
informed consent form. Then, the patient will undergo a
clinical interview and fill out the paper-and-pencil
screening survey describing his/her sociodemographic
and clinical characteristics. This first data collection and
screening will be performed by specially trained psychol-
ogists with the objective of assessing whether the partici-
pants meet the eligibility criteria to participate in the
study. If the participant meets the inclusion criteria, an
independent researcher will implement randomization
by telephone to avoid predictability.
Inclusion criteria will be as follows: a) older than 18
years; b) DSM-5 diagnosis of Major Depression or Dys-
thymia or mild or moderate depression, expressed as a
score between 5 and 14 on the Patient Health Question-
naire (PHQ) [35]; c) depressive symptoms present for at
least 2 months; d) having a computer and Internet at
home; e) being able to read and understand the Spanish
language; and f) willingness to participate in the study
and sign the written informed consent form.
Exclusion criteria include: a) any diagnosis of a disease
that may affect the central nervous system (brain path-
ology, traumatic brain injury, or dementia); b) other psy-
chiatric diagnoses or acute psychiatric illnesses (severe
range of depression, substance dependence or abuse, his-
tory of schizophrenia or other psychotic disorders, and
eating disorders), except for anxious pathology or per-
sonality disorders; c) any medical, infectious, or degen-
erative disease that may affect mood, presence of
delusional ideas, or hallucinations consistent or not with
mood and suicide risk. Participants in both the TAU
group and the MBI conditions can continue their medi-
cation (mainly anxiolytics and antidepressants) if there
are no increases, unless they are necessary. However,
they will not be allowed to receive any other psycho-
logical treatment during the study period (unless it is
necessary for ethical reasons and it benefits the partici-
pant). Cases where the medication is increased or an-
other psychological treatment is needed will be excluded
from the analysis.
Randomization and blinding
Participants who meet the inclusion criteria for the study
will receive a code from the screening assessors in order
to maintain participants’ confidentiality. An independent
researcher unaware of the study characteristics will per-
form the randomization process. In order to randomly
allocate the participants to one of the three conditions
referred to above (face-to-face MBI + TAU, Internet de-
livered MBI + TAU, and TAU alone), a computer-
generated random number sequence (https://www.ran-
domizer.org/) will be used by means of a simple alloca-
tion strategy and a 1:1:1 rate. After informing the
patients of the study characteristics, they will accept to
participate before the random allocation and without
knowing the condition to which they will be allocated.
The researcher who administers baseline assessments
will be blind to the patients’ treatment group. This re-
searcher will be different from the one – also blinded –
who administers the other measures throughout the
study. Patients in the Internet-delivered MBI arm will
complete all the measures online. GPs will be blind, but
the face-to-face MBI therapist will not. Participants will
not be blind to the treatment condition for ethical and
practical reasons.
Sample size
The sample size estimation was based on testing
whether the trend in the change is different between the
intervention groups throughout the 4 time points.
Firstly, we assumed that MBI groups would be able to
present moderately high effects, compared to “TAU
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alone”, on the BDI-II at post-treatment. To
operationalize this, we considered a standardized differ-
ence between arms on the main outcome of d = 0.7,
which corresponds to the average effect observed in ten
studies comparing MBIs with different wait-list condi-
tions [36] and surpasses the 0.5 standard deviation cri-
terion considered clinically relevant in previous studies
[37, 38]. A preceding study by our research group with
mild or moderate depressed patients in a similar Spanish
PC setting found BDI-II means and standard deviations
(SDs) of 22 and 5, respectively [20]. The inclusion cri-
teria used in this study restricted the entry of mild or
moderate depressed patients, thus reducing the SD com-
pared to the general population and presenting a less
skewed distribution of the data, as we predict will occur
in the present study. The effect size referred to above
corresponds to a difference of 3.5 points, which implies
a reduction of slightly more than 15% in the BDI-II scale
used. According to the GLIMMPSE v2.0.0 – time x
group interaction in a general linear repeated measures
(RM) design – and GPower v3.1.9.4 – ANOVA test for
RM within-between interaction – statistical tools, con-
sidering the referred difference between the “face-to-face
MBI + TAU” vs. “TAU alone” groups of depressed pa-
tients, which corresponds to a partial eta square value of
roughly 0.09 and an effect size f of 0.31, with a common
mean at baseline of 22, a mean at post-test of 16 and
19.5 respectively, and a mean at post-test of 17 for the
“Internet delivered MBI + TAU” condition, and assum-
ing a one point reduction in each group at each follow-
ing time point, a baseline correlation of 0.6 and a decay
rate of 0.35, assuming a common SD of 5, a 5% signifi-
cance level, a statistical power of 80% using a 1:1:1 ratio,
and an univariate approach to RM with Greenhouse-
Geisser correction [39], we needed 33 subjects in each
group. Because we expected a dropout rate of approxi-
mately 20% [40], we inflated the numbers to reach a
total sample size of 120 patients, 40 per arm [41].
Interventions
Mindfulness-based interventions (MBIs)
The two MBIs (face-to-face and Internet delivered) are
composed of an initial face-to-face group (6-8 partici-
pants) session to introduce the therapeutic modules, ex-
plain how mindfulness can help patients with their
problem, and motivate them to change. In the case of
online patients, the therapist will also explain how to
enter the web page where the therapeutic modules are
located. Thus, both conditions are composed of four
modules, face-to-face or online, depending on the
assigned condition. Regardless of the condition, all the
patients will receive their corresponding TAU.
- “Face-to-face MBI” sessions will be carried out in a
group format (between 6 and 8 participants) and with
weekly sessions lasting 90min each for 4 weeks. The
therapist will explain the different modules and how to
do the mindfulness exercises. The mindfulness activities
will be performed in the sessions, and then participants
will have to practice at home. All the materials will be
delivered in print form, except the audios, which will be
sent by e-mail. However, the audios will also be tran-
scribed in the printed modules. Module contents are the
same as those in the online intervention. These contents
have been adapted from an online format previously
used [10] to a traditional format for their application in
this study. If a participant does not attend a session, the
corresponding materials will be delivered to him/her,
and s/he will be able to ask any questions about them in
the next session.
- “Internet-based MBI” will be carried out online and
individually through a web platform (https://www.psico-
logiaytecnologia.com/) where participants will have to
introduce a login and a password to enter their corre-
sponding profiles. The duration of each module will be
approximately 60-90 min, depending on the participant’s
pace and time availability, and the estimated program
duration for most people will be between 4 and 8 weeks
[10]. Some meta-analyses have shown that attrition rates
are higher when no therapist support is provided to pa-
tients in Internet-based programs [21, 42]. For this rea-
son, when the patients complete the second module
(halfway through the program), they will receive a phone
call from the therapist who will monitor their progress
and motivate them to continue and adhere to the pro-
gram. However, no additional therapeutic content will
be offered.
Before the therapeutic modules, there is an introduc-
tory module (M0) with basic information about emo-
tional disorders, the protocol contents, the importance
of evaluation and registers, and ambivalence as a natural
part of change, as well as an exercise where the partici-
pant fills in a table with the costs and benefits of the
change process. This module is carried out face-to-face
in both treatment conditions before the pre-treatment
assessment and the intervention, and it is presented indi-
vidually to the Internet-based MBI arm and in group
format to the face-to-face MBI arm.
The therapeutic modules are oriented toward working
on different formal psychological mindfulness practices
that can help to decrease depressive symptomatology.
These practices emphasize thought management, accept-
ance, values orientation, and compassion over a short
period of time. For this reason, a brief intervention is
proposed, composed of four modules (a brief description
of each module is presented below).
M1. Getting to know mindfulness This module will
show what mindfulness is, prejudices about it,
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inattention problems in our society, some mindfulness
benefits, and recommendations for practicing it. In this
module, participants will perform the raisin mindfulness
exercise, which is widely used as an introduction to
mindfulness meaning.
M2. Establishing formal and informal practices This
module will explain the importance of formal and infor-
mal practice. To do so, different techniques such as the
three-minute practice will be demonstrated.
M3. Thoughts management, body scan practice, and
values This module aims to show the importance of
thoughts and values in our emotions and lives, and the
need to recognize them. It will also include the body
scan practice.
M4. Self-compassion and integrating mindfulness in
everyday life This module works on how to establish a
mindfulness practice habit in order to consolidate the
use of this technique. It will also include a self-
compassion practice, which has shown its efficacy in
treating depression symptoms [10, 33].
These modules can be done step-by-step. When a pa-
tient has finished a module, it can be reviewed as many
times as necessary. Each module includes: content expla-
nations, self-assessment questions to test whether partic-
ipants have understood the contents, exercises to
practice, and homework assignments.
Treatment as usual (TAU)
Participants in the treatment as usual (TAU) arm will
continue to be treated by their GPs in their correspond-
ing health centers. The treatments offered by the GPs
are mainly pharmacological, with antidepressants and/or
anxiolytics being the most frequent medications. In cases
of suicide risk or other severe symptoms or unexpected
effects during the study, the patient will be referred to
specialized mental health care services and excluded
from the data analysis.
Instruments
The evaluations will be performed at screening, baseline,
post-treatment, and 6- and 12-month follow-ups. All
variables and assessment periods of the study can be
found in Table 1. Scores on depression, negative and
positive affect, and opinions about the modules will also
be obtained after each completed module in the face-to-
face and Interned-based MBIs. Participants in the TAU
group will report their general opinion about the treat-
ment as usual received at the end of the program.
Diagnosis interview
-Mini international neuropsychiatric interview V-
5.0.0 (MINI) The MINI V-5.0.0 interview is structured
based on the psychiatric diagnoses of DSM-IV and ICD-
10 [43, 44]. To administer it, clinicians only need a brief
training and a short period of time that oscillates around
15 min. This interview has proven to be an accurate
interview for use in multicenter clinical trials. The MINI
interview will be used in the screening to determine
Table 1 Study outcomes
Instruments Assessment Area Time of assessmenta
Sociodemographic Gender, age, marital status, education, occupation, economical level. Screening
MINI Psychiatric diagnosis Screening
PHQ-9 Severity of depression Screening, post-module, post-treatment and follow-ups
CSRI Health and social services use Screening and 12-month follow-up
BDI-II Severity of depression Baseline, post-treatment and follow-ups
SF-12 Health-related quality of life Baseline, post-treatment and follow-ups
EQ-5D Health-related quality of life Baseline and follow-ups
PANAS Positive and negative Affect Baseline, post-modules and follow-ups
FFMQ Facets and factors of mindfulness Baseline and follow-ups
PHI Remembered and experienced well-being Baseline and follow-ups
ETS Treatment expectations Baseline
OTS Treatment opinions Post-treatment
MINI Mini-International Neuropsychiatric Interview, PHQ-9 Patient Health Questionnaire-9, CSRI Client Service Receipt Inventory, BDI-II Beck Depression Inventory-II,
SF-12 Short Form-12 Health Survey, EQ-5D EuroQoL-5D Questionnaire, PANAS Positive and Negative Affect Scale, FFMQ Five Facet Mindfulness Questionnaire, PHI
Pemberton Happiness Index, ETS Expectation of Treatment Scale, OTS Opinion of Treatment Scale.
aWaves: screening, baseline, post-treatment (6 weeks for the “face-to-face MBI + TAU” and “TAU alone” or 12 weeks after baseline for the “Internet-delivered MBI +
TAU”), post-module (after each individual module for the “face-to-face MBI + TAU” and for the “Internet-delivered MBI + TAU”), follow-ups (both 6 and 12 month
follow-up measurements)
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whether a potential participant meets the inclusion criteria
for Major Depression or Dysthymia. However, for cost
reasons, the MINI interview will not be applied at post-
treatment or follow-up. The MINI V-5.0.0 has been trans-
lated and validated in the Spanish language [31, 35].
Primary outcome
-Beck Depression Inventory II (BDI-II) [45] The BDI-
II total score, as a continuous variable, will be used as
the primary outcome measure at post-test. It has been
widely used in clinical research to assess changes in de-
pression severity [20]. Additionally, the BDI-II has
shown good sensitivity and specificity in detecting major
depressive disorder in the Spanish-speaking population
[46]. It is composed of 21 items about symptoms charac-
terizing major depression. The BDI-II total score can be
obtained by adding up the answers, from a minimum of
0 to a maximum of 63 points. The BDI-II Spanish ver-
sion has shown high internal consistency in both general
(α = 0.87) and clinical populations (α = .89) [47].
Secondary outcomes
-Sociodemographic variables The sociodemographic
variables that will be collected are the following: gender,
age, marital status (single, married/relationship, sepa-
rated/divorced, and widowed), education (no studies but
can read and write, primary education, secondary educa-
tion, University studies, and others), occupation (stu-
dent, housework, unemployed, employee, sick leave,
retired, disability, and other), and economic level (< 1
minimum inter-professional salary –MIS, 1-2 MIS, 2-4
MIS, and > 4 MIS).
-The Patient Health Questionnaire 9 (PHQ-9) [48]
This questionnaire is also one of the most widely used
in research to evaluate depression severity. It is a brief
instrument consisting of 9 items scored from 0 (“not at
all”) to 3 (“nearly every day”), and it is completed by the
patient. In this trial, the Spanish validated version will be
used [35].
-Positive and negative affect scale (PANAS) [49] This
questionnaire is composed of 20 items and two inde-
pendent dimensions: positive affect (PA) and negative ef-
fect (NA). Each scale has 10 items, and the score range
for each is from 10 to 50. The psychometric properties
of the PANAS are satisfactory. The Spanish version will
be used [50].
-The Pemberton Happiness Index (PHI) [51] The PHI
is used to assess remembered well-being (general, he-
donic, eudaimonic, and social well-being) through 11
items rated on a Likert scale ranging from 0 (strongly dis-
agree) to 10 (strongly agree). In addition, experienced
well-being (positive and negative emotional events that
may have happened the day before) is also measured
through 10 items answered dichotomously (yes or no). In
this study, the Spanish validated version will be used [51].
Other outcomes
Health-related quality of life
-Sort Form-12 Health Survey (SF-12) [52] This instru-
ment measures health-related quality of life and general
functioning. The SF-12 consists of 12 items that have
demonstrated adequate psychometric properties in its
Spanish version [53, 54].
-EuroQoL-5D (EQ-5D) [55, 56] The EQ-5D is an in-
strument commonly used to measure health-related
quality of life. Participants self-report problems in the
following five domains: mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression. Each one
of them is divided into three severity levels correspond-
ing to no problems, some problems, and extreme prob-
lems, which makes it possible to obtain a population-
based score or societal index (SI). In addition, the par-
ticipant will self-assess his/her current health status on a
10 cm vertical line where the best and worst imaginable
health states score 100 and 0, respectively. The scores
for these health-related states will be assigned using the
readily available Spanish population rates [40, 41].
Cost-effectiveness
-Client Service Receipt Inventory (CSRI) [57] This
questionnaire is used to collect information about
healthcare uses and social care services, in addition to
other economic impacts (such as time off work due to
illness). The variant used in this study was designed to
collect retrospective data on service utilization during
the 6 months prior to the assessment. The Spanish vali-
dated version will be used [58].
Therapeutic process measure
-Five Facet Mindfulness Questionnaire (FFMQ) [59]
This questionnaire assesses five factors of mindfulness
through 39 items: observing (8 items), describing (8
items), acting with awareness (8 items), not judging
inner experience (8 items), and not reacting to inner ex-
perience (7 items). Items are answered on a Likert-type
scale ranging from 1 (“never or very rarely true”) to 5
(“very often or always true”). The FFMQ has been shown
to have good internal consistency and reliability in its
Spanish validation [60].
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Treatment expectations, opinions, and completion
-Expectation of treatment scale (ETS) and opinion of
treatment scale (OTS) These scales are adapted from
Borkovec and Nau [61]. They include 5 items, rated
from 0 (“not at all”) to 10 (“very much”), that address
how logical the treatment seems, to what extent it satis-
fies the patient, whether it could be used to treat other
psychological problems, its usefulness for the patient’s
specific problem, and to what extent the treatment
might be aversive. The expectation scale will be applied
once the treatment rationale has been explained and
after M0 to measure subjective patient expectations
about the treatment they are about to receive. The opin-
ion scale is administered when the patients have com-
pleted the treatment to assess their satisfaction with it.
In the case of the MBI groups, a question will be intro-
duced related to the opinion about each individual mod-
ule (e.g. “To what extent has this module been useful to
you?“), using a visual analogue scale ranging from 0
(“nothing”) to 10 (“very much”), as well as two questions
related to reviewing the materials (“Have you reviewed
the last module seen in the session and all the materials
it includes?”) and homework completion (“Have you
done the tasks to train at home?”), with two possible re-
sponses (yes vs. no). In addition, a module completion
register will be filled out.
Data analysis
The results will be reported following CONSORT rec-
ommendations [62, 63]. Socio-demographic and clinical
information will be described at baseline by means of
frequencies and percentages (e.g. categorical variables)
or means and standard deviations (e.g. continuous vari-
ables), and treatment conditions will be compared to en-
sure the success of the randomization, using the chi-
square or Fisher tests and one-way ANOVA.
Main analysis
The efficacy of the “face-to-face MBI + TAU” group
compared to the “TAU alone” group will be estimated
based on the main BDI-II outcome, which will be con-
sidered a continuous variable. Multilevel mixed-effects
models will be developed by means of a RM design on
an intention-to-treat (ITT) basis, using the restricted
maximum likelihood (REML) method, in order to pro-
duce unbiased estimates of variance/covariance parame-
ters [54]. Non-standardized slopes and 95% confidence
intervals (95% CI) will be calculated by adjusting those
variables that show significant differences between
groups at baseline. In order to study the specific trajec-
tories of each group throughout the trial and determine
whether possible differences between groups are consist-
ent over time, the ‘group x time’ interactions will be
calculated. Cohen’s d effect sizes will be calculated at
each time point using the combined standard deviation
at baseline [64]. Effect sizes are small when d ≤ 0.2;
medium when d = 0.5; and large when d ≥ 0.8 [65].
Secondary analysis
The efficacy of the “face-to-face MBI + TAU” group
compared to the “TAU alone” group with regard to the
secondary outcomes and the other measures, and the ef-
ficacy of the “Internet-delivered MBI + TAU” compared
to the “TAU alone”, as well as the exploratory compari-
son of the “face-to-face MBI + TAU” and “Internet-deliv-
ered MBI + TAU” on the primary and secondary
outcomes, will be calculated following the same analyt-
ical strategy used for the main analysis. Per protocol
analysis will also be performed, considering only those
patients who attend at least 3 modules (out of 4). The
clinical significance of improvements between groups
will be explored by calculating the absolute risk reduc-
tion and number needed to treat (NNT) (and their 95%
CI). We will use two criteria for improvement: a) chan-
ging to a less severe cluster in the BDI-II compared to
the one the patient was allocated to at baseline; c) calcu-
lating the clinical significance of improvements by estab-
lishing both the cut-off point and reliable change index
on the BDI-II total score using the Jacobson and Truax
method [66]. Additionally, possible differences in PHQ-9
and PANAS will be explored throughout the MBI mod-
ules using mixed models.
Cost analysis
Cost will be calculated from healthcare and societal per-
spectives during the 12 months before the screening and
during the 12months before the last follow-up. The cost
of pharmacological therapy, medical tests, and use of
health services will be added together to calculate direct
healthcare costs. Indirect costs such as loss of productiv-
ity will be calculated considering the minimum daily
wage in Spain and the number of sickness absence days.
Total costs will be estimated by adding up direct and in-
direct costs in €. The effectiveness of the interventions
will be estimated as the difference between the BDI-II
score at baseline and at follow-up, and utility will be es-
timated using quality-adjusted life-year (QALYs) at
follow-up. QALYs will be calculated using the area-
under-the-curve (AUC). Cost-effectiveness will be ana-
lyzed through the estimation of incremental cost-
effectiveness ratios (ICERs). Cost-utility will be calcu-
lated through the estimation of incremental cost-utility
ratios (ICURs). Cost-utility planes will be plotted.
Level of significance
An alpha level of 0.05 will be established using a two-
tailed test. The probability values relative to the main
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analysis will be adjusted according to Benjamini-
Hochberg’s correction for multiple comparisons, but the
secondary and exploratory analyses will not be corrected.
Discussion
Consistent with the evidence, a large percentage of pa-
tients seen in PC services are being treated long-term
with antidepressants, showing high relapse rates when
trying to stop the medication [67], and many of them
are referred to already overloaded specialized mental
health services [68]. Therefore, there is a need to offer
new forms of treatment that provide stability or im-
provement before moving on to specialized care. Cur-
rently, a growing number of studies show the efficacy of
MBIs for emotional disorders, but only a few have fo-
cused on PC settings [69]. In this context, the present
study protocol describes a randomized controlled clin-
ical trial that has the main objective of evaluating a low-
intensity MBI plus TAU for the treatment of depression
in PC services compared to TAU alone.
Additionally, the advantages of brief Internet-delivered
psychotherapy for depression could provide an alterna-
tive to current treatments and a possible solution for
existing problems, especially with regard to waiting lists,
lack of time, and health costs of PC Spanish services.
Moreover, the effectiveness of Internet-based treatments
for this disorder has also been demonstrated, and this
kind of protocol can help to spread evidence-based
treatments, so that more people can benefit from them
[21, 70]. Specifically, mindfulness has been proposed as
a potential non-drug therapy for mild-to-moderate de-
pression [71] and for preventing depression relapses
[72]. The study of mindfulness-based online interven-
tions is increasing due to their good results and the ben-
efits that have begun to be observed [27, 31].
The study has various strengths. First, to the best of
our knowledge, this is the first Spanish randomized con-
trolled clinical trial to apply a face-to-face brief MBI,
and the second study to apply an online low-intensity
MBI in PC settings [10]. Second, this study proposes
two different ways to apply mindfulness treatments,
which will allow us to compare them with TAU and find
out which one is more cost-effective. Lastly, this will be
the first study to compare a traditional face-to-face vs.
online mindfulness program in the Spanish PC context,
although in an exploratory way.
The limitations are similar to those of the study car-
ried out by Castro et al. [10], who refer to possible nega-
tive attitudes from GPs about recommending this
treatment, and high dropout rates in the treatment
groups, especially in the control group. To minimize the
effect of negative attitudes, the intervention characteris-
tics will be explained in depth to the clinicians involved
in the trial. In order to prevent dropouts, we will send
emails to the participants reminding them to continue
and complete the trial requirements. Another limitation
is the possible small statistical power to obtain signifi-
cant results in the comparison of the face-to-face and
online MBI groups, but, as mentioned above, this study
will be considered a pilot exploration of possible effect
sizes to guide future research. Other difficulties that may
appear could be related to recruitment because some
people might not have access to the Internet at home, or
they might even prefer traditional treatments (due to un-
awareness of the benefits of the new treatments and
technologies) or be influenced by the depressive symp-
toms themselves (apathy, anhedonia, etc.).
Clinical implications
Positive results of this randomized controlled clinical trial
may have an important impact on public PC and mental
health settings because applying a brief psychotherapeutic
protocol to treat mild or moderate depression could help
to decrease the overload of the public mental health sys-
tem. On the one hand, it could reduce costs, waiting lists,
hours of clinical assistance, and hours of face-to-face
treatment. On the other hand, it offers treatment alterna-
tives beyond antidepressant medication that can help to
reduce depressive symptoms and slow down the inclusion
of patients in mental health services by offering high-
quality and flexible interventions in PC [73].
Finally, benefits of mindfulness in different disorders
and in quality of life outcomes have been reported by
several studies [74, 75]. Thus, although this study fo-
cuses mainly on depression, this proposal could also be
used as a trans-diagnostic protocol in other comorbid
psychological problems or emotional disorders (e.g. anx-
iety disorders) [71]. However, this is a brief treatment
protocol, and research should be carried out in this re-
gard. In conclusion, significant results from this trial
could be beneficial for society and public health as a
whole and encourage further research along these lines.
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